Registration number:
London Allergy and Immunology Centre Ltd
for the Year Ended 2 February 2024
London Allergy and Immunology Centre Ltd
Contents
Company Information |
|
Director's Report |
|
Accountants' Report |
|
Abridged Profit and Loss Account |
|
Statement of Comprehensive Income |
|
Abridged Balance Sheet |
|
Statement of Changes in Equity |
|
Notes to the Unaudited Abridged Financial Statements |
|
iXBRL Detailed Profit and Loss Account |
London Allergy and Immunology Centre Ltd
Company Information
Director |
Mr Michael Rudenko |
Company secretary |
Mr Michael Rudenko |
Registered office |
|
Accountants |
|
London Allergy and Immunology Centre Ltd
Director's Report for the Year Ended 2 February 2024
The director presents his report and the abridged financial statements for the year ended 2 February 2024.
Director of the company
The director who held office during the year was as follows:
Principal activity
The principal activity of the company is Specialist Medical Practice
Small companies provision statement
This report has been prepared in accordance with the special provisions relating to companies subject to the small companies regime within Part 15 of the Companies Act 2006.
Approved and authorised by the
......................................... |
Chartered Accountants' Report to the Director on the Preparation of the Unaudited Statutory Accounts of
London Allergy and Immunology Centre Ltd
for the Year Ended 2 February 2024
In order to assist you to fulfil your duties under the Companies Act 2006, we have prepared for your approval the accounts of London Allergy and Immunology Centre Ltd for the year ended 2 February 2024 as set out on pages 4 to 12 from the company's accounting records and from information and explanations you have given us.
As a practising member firm of the Institute of Chartered Accountants in England and Wales (ICAEW), we are subject to its ethical and other professional requirements which are detailed at
http://www.icaew.com/regulation.
This report is made solely to the Board of Directors of London Allergy and Immunology Centre Ltd, as a body, in accordance with the terms of our engagement letter. Our work has been undertaken solely to prepare for your approval the accounts of London Allergy and Immunology Centre Ltd and state those matters that we have agreed to state to the Board of Directors of London Allergy and Immunology Centre Ltd, as a body, in this report in accordance with ICAEW Technical Release 07/16 AAF. To the fullest extent permitted by law, we do not accept or assume responsibility to anyone other than London Allergy and Immunology Centre Ltd and its Board of Directors as a body for our work or for this report.
It is your duty to ensure that London Allergy and Immunology Centre Ltd has kept adequate accounting records and to prepare statutory accounts that give a true and fair view of the assets, liabilities, financial position and profit of London Allergy and Immunology Centre Ltd. You consider that London Allergy and Immunology Centre Ltd is exempt from the statutory audit requirement for the year.
We have not been instructed to carry out an audit or a review of the accounts of London Allergy and Immunology Centre Ltd. For this reason, we have not verified the accuracy or completeness of the accounting records or information and explanations you have given to us and we do not, therefore, express any opinion on the statutory accounts.
......................................
Hackney
London
E8 2HW
London Allergy and Immunology Centre Ltd
Abridged Profit and Loss Account for the Year Ended 2 February 2024
Note |
2024 |
2023 |
|
Gross profit |
|
|
|
Administrative expenses |
( |
( |
|
Other interest receivable and similar income |
|
|
|
Profit before tax |
|
|
|
Tax on profit |
( |
( |
|
Profit for the financial year |
|
|
The above results were derived from continuing operations.
The company has no recognised gains or losses for the year other than the results above.
London Allergy and Immunology Centre Ltd
Statement of Comprehensive Income for the Year Ended 2 February 2024
2024 |
2023 |
|
Profit for the year |
|
|
Total comprehensive income for the year |
|
|
London Allergy and Immunology Centre Ltd
(Registration number: 07935559)
Abridged Balance Sheet as at 2 February 2024
Note |
2024 |
2023 |
|
Fixed assets |
|||
Tangible assets |
|
|
|
Current assets |
|||
Cash at bank and in hand |
|
|
|
Creditors: Amounts falling due within one year |
( |
( |
|
Net current assets |
|
|
|
Net assets |
|
|
|
Capital and reserves |
|||
Called up share capital |
100 |
100 |
|
Retained earnings |
2,990,469 |
2,767,399 |
|
Shareholders' funds |
2,990,569 |
2,767,499 |
For the financial year ending 2 February 2024 the company was entitled to exemption from audit under section 477 of the Companies Act 2006 relating to small companies.
Director's responsibilities:
• |
|
• |
The director acknowledges his responsibilities for complying with the requirements of the Act with respect to accounting records and the preparation of accounts. |
These financial statements have been prepared in accordance with the special provisions relating to companies subject to the small companies regime within Part 15 of the Companies Act 2006.
All of the company’s members have consented to the preparation of an Abridged Profit and Loss Account and an Abridged Balance Sheet in accordance with Section 444(2A) of the Companies Act 2006.
Approved and authorised by the
.........................................
Mr Michael Rudenko
Company secretary and director
London Allergy and Immunology Centre Ltd
Statement of Changes in Equity for the Year Ended 2 February 2024
Share capital |
Retained earnings |
Total |
|
At 3 February 2023 |
|
|
|
Profit for the year |
- |
|
|
Dividends |
- |
( |
( |
At 2 February 2024 |
|
|
|
Share capital |
Retained earnings |
Total |
|
At 3 February 2022 |
|
|
|
Profit for the year |
- |
|
|
Dividends |
- |
( |
( |
At 2 February 2023 |
100 |
2,767,399 |
2,767,499 |
London Allergy and Immunology Centre Ltd
Notes to the Unaudited Abridged Financial Statements for the Year Ended 2 February 2024
General information |
The company is a private company limited by share capital, incorporated in England & Wales.
The address of its registered office is:
England
These financial statements were authorised for issue by the
Accounting policies |
Summary of significant accounting policies and key accounting estimates
The principal accounting policies applied in the preparation of these financial statements are set out below. These policies have been consistently applied to all the years presented, unless otherwise stated.
Statement of compliance
These abridged financial statements have been prepared in accordance with Financial Reporting Standard 102 Section 1A smaller entities - 'The Financial Reporting Standard applicable in the United Kingdom and Republic of Ireland' and the Companies Act 2006 (as applicable to companies subject to the small companies' regime).
Basis of preparation
These abridged financial statements have been prepared using the historical cost convention except that as disclosed in the accounting policies certain items are shown at fair value.
Going concern
The financial statements have been prepared on a going concern basis.
Revenue recognition
Turnover comprises the fair value of the consideration received or receivable for the sale of goods and provision of services in the ordinary course of the company’s activities. Turnover is shown net of sales/value added tax, returns, rebates and discounts.
The company recognises revenue when:
The amount of revenue can be reliably measured;
it is probable that future economic benefits will flow to the entity;
and specific criteria have been met for each of the company's activities.
Tax
The tax expense for the period comprises current tax. Tax is recognised in profit or loss, except that a change attributable to an item of income or expense recognised as other comprehensive income is also recognised directly in other comprehensive income.
London Allergy and Immunology Centre Ltd
Notes to the Unaudited Abridged Financial Statements for the Year Ended 2 February 2024
The current income tax charge is calculated on the basis of tax rates and laws that have been enacted or substantively enacted by the reporting date in the countries where the company operates and generates taxable income.
Tangible assets
Tangible assets are stated in the balance sheet at cost, less any subsequent accumulated depreciation and subsequent accumulated impairment losses.
The cost of tangible assets includes directly attributable incremental costs incurred in their acquisition and installation.
Depreciation
Depreciation is charged so as to write off the cost of assets, other than land and properties under construction over their estimated useful lives, as follows:
Asset class |
Depreciation method and rate |
Office Equipment |
33% on Straight line basis |
Cash and cash equivalents
Cash and cash equivalents comprise cash on hand and call deposits, and other short-term highly liquid investments that are readily convertible to a known amount of cash and are subject to an insignificant risk of change in value.
Trade creditors
Trade creditors are obligations to pay for goods or services that have been acquired in the ordinary course of business from suppliers. Accounts payable are classified as current liabilities if the company does not have an unconditional right, at the end of the reporting period, to defer settlement of the creditor for at least twelve months after the reporting date. If there is an unconditional right to defer settlement for at least twelve months after the reporting date, they are presented as non-current liabilities.
Trade creditors are recognised initially at the transaction price and subsequently measured at amortised cost using the effective interest method.
Share capital
Ordinary shares are classified as equity. Equity instruments are measured at the fair value of the cash or other resources received or receivable, net of the direct costs of issuing the equity instruments. If payment is deferred and the time value of money is material, the initial measurement is on a present value basis.
Dividends
Dividend distribution to the company’s shareholders is recognised as a liability in the financial statements in the reporting period in which the dividends are declared.
Defined contribution pension obligation
A defined contribution plan is a pension plan under which fixed contributions are paid into a pension fund and the company has no legal or constructive obligation to pay further contributions even if the fund does not hold sufficient assets to pay all employees the benefits relating to employee service in the current and prior periods.
Contributions to defined contribution plans are recognised as employee benefit expense when they are due. If contribution payments exceed the contribution due for service, the excess is recognised as a prepayment.
London Allergy and Immunology Centre Ltd
Notes to the Unaudited Abridged Financial Statements for the Year Ended 2 February 2024
Staff numbers |
The average number of persons employed by the company (including the director) during the year, was
Profit before tax |
Arrived at after charging/(crediting)
2024 |
2023 |
|
Depreciation expense |
|
|
Tangible assets |
Land and buildings |
Furniture, fittings and equipment |
Motor vehicles |
Total |
|
Cost or valuation |
||||
At 3 February 2023 |
|
|
- |
|
Additions |
|
|
|
|
At 2 February 2024 |
|
|
|
|
Depreciation |
||||
At 3 February 2023 |
- |
|
- |
|
Charge for the year |
- |
|
|
|
At 2 February 2024 |
- |
|
|
|
Carrying amount |
||||
At 2 February 2024 |
|
|
|
|
At 2 February 2023 |
|
|
- |
|
Included within the net book value of land and buildings above is £851,075 (2023 - £844,619) in respect of freehold land and buildings.
Debtors |
Debtors includes £Nil (2023 - £Nil) due after more than one year.
London Allergy and Immunology Centre Ltd
Notes to the Unaudited Abridged Financial Statements for the Year Ended 2 February 2024
Share capital |
Dividends |
Interim dividends paid
2024 |
2023 |
|||
Interim dividend of £ |
|
|
||
Related party transactions |
London Allergy and Immunology Centre Ltd
Notes to the Unaudited Abridged Financial Statements for the Year Ended 2 February 2024
Director's remuneration
The director's remuneration for the year was as follows:
2024 |
2023 |
|
Remuneration |
|
|
Contributions paid to money purchase schemes |
|
- |
109,900 |
12,750 |
London Allergy and Immunology Centre Ltd
iXBRL Detailed Profit and Loss Account for the Year Ended 2 February 2024
2024 |
2023 |
|
Turnover/revenue |
|
|
Cost of sales |
||
Opening stock/inventories |
- |
- |
Purchase of raw materials and consumables |
( |
( |
Closing stock/inventories |
- |
- |
Gross profit |
785,043 |
635,057 |
Distribution costs |
||
Administrative expenses |
||
Audit and accountancy other services |
( |
( |
Rent, rates and services costs |
( |
( |
Utilities costs |
( |
( |
Other repairs and maintenance costs |
( |
( |
Depreciation of fixed assets |
( |
( |
Wages and salaries excluding directors |
( |
( |
Pension costs defined contribution schemes excluding directors |
( |
- |
Staff costs excluding directors |
( |
( |
Salaries and fees, directors |
( |
( |
Company contributions to money purchase plans, directors |
( |
- |
Staff costs, directors |
( |
( |
Travel and subsistence |
( |
( |
Legal and professional costs |
( |
( |
Insurance costs |
( |
( |
Charitable donations |
( |
( |
Other costs |
( |
( |
Other operating income |
||
Other items |
||
Profit on ordinary activities before finance charges and interest |
320,709 |
458,153 |
Bank interest and similar income receivable |
|
|
Profit on ordinary activities before taxation |
|
|
Tax on profit or loss on ordinary activities |
( |
( |
Profit for the financial year |
|
|